If the medical insurance fund is not enough, some drugs will be transferred out of the catalogue, which will have a great impact on patients with drug needs. They will no longer enjoy low-priced drugs, and will face high medical expenses, which will have a great economic burden on long-term drug users, especially those with difficult family conditions and many patients. With the rapid development of medical insurance, the national medical insurance drug list is dynamically adjusted every year. In the past four years, more than 500 drugs have been included in the list. After negotiations, the price of drugs dropped significantly, and local supplementary drugs were basically replaced by drugs in the national catalogue. To balance the affordability of local medical insurance funds.
It is a phased measure in the early stage of the establishment of China's medical insurance system to replenish some drugs in various provinces. Because there are obvious differences in the quantity and types of drugs supplemented in different places, there will also be great differences in the medical insurance benefits and benefits enjoyed by medical insurance patients in different regions. In some areas, the inclusion of some drugs with extremely low utilization rate in the medical insurance catalogue will also cause a waste of medical insurance resources and violate the principle of medical insurance fairness. Through the basic unification of the scope of medical insurance drugs in the whole country, without increasing the burden on patients, further improving the list of medical insurance drugs can better facilitate medical treatment and ensure the well-being of more citizens.